secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2026-08-17T10:01:31+00:00
Accession:  0001193125-26-353141
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Quince Therapeutics schedules special meeting for Series C conversion and share issuance
--------------------------------------------------------------------------------

- Quince Therapeutics will hold a special meeting to approve issuance of shares upon conversion of 211,301.868 Series C Preferred shares into 10,987,728 common shares.
- Pro forma balance sheet as of June 30, 2026 reflects reclassification of $6.3 million Series C warrant liability to equity.
- The share issuance may exceed 20% of outstanding common stock and could result in change of control under Nasdaq Listing Rule 5635(b).
- Company filed unaudited pro forma condensed consolidated financial information with the SEC on August 17, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526353141/0001193125-26-353141-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312526353141/d379347d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-353141

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer